Spectral Medical Inc
TSX:EDT

Watchlist Manager
Spectral Medical Inc Logo
Spectral Medical Inc
TSX:EDT
Watchlist
Price: 0.495 CAD 2.06% Market Closed
Market Cap: 140m CAD
Have any thoughts about
Spectral Medical Inc?
Write Note

Spectral Medical Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Spectral Medical Inc
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Spectral Medical Inc
TSX:EDT
Total Current Liabilities
CA$33.9m
CAGR 3-Years
150%
CAGR 5-Years
107%
CAGR 10-Years
29%
B
Bright Minds Biosciences Inc
CNSX:DRUG
Total Current Liabilities
CA$638.6k
CAGR 3-Years
62%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Total Current Liabilities
$52.9m
CAGR 3-Years
6%
CAGR 5-Years
14%
CAGR 10-Years
21%
ESSA Pharma Inc
NASDAQ:EPIX
Total Current Liabilities
$3.3m
CAGR 3-Years
-5%
CAGR 5-Years
-10%
CAGR 10-Years
19%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Total Current Liabilities
$78.6m
CAGR 3-Years
28%
CAGR 5-Years
42%
CAGR 10-Years
40%
Covalon Technologies Ltd
XTSX:COV
Total Current Liabilities
CA$4.4m
CAGR 3-Years
-41%
CAGR 5-Years
-24%
CAGR 10-Years
9%
No Stocks Found

Spectral Medical Inc
Glance View

Market Cap
140m CAD
Industry
Biotechnology

Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 31 full-time employees. The firm has conducted a Phase III clinical trial for its lead product, PMX (Toraymyxin PMX-20R), which is for the treatment of patients with septic shock and endotoxemia that is measured by the Company’s Endotoxin Activity Assay (EAA). EAA and PMX are both Health Canada licensed and commercially available in Canada. The firm through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market.

EDT Intrinsic Value
0.038 CAD
Overvaluation 92%
Intrinsic Value
Price

See Also

What is Spectral Medical Inc's Total Current Liabilities?
Total Current Liabilities
33.9m CAD

Based on the financial report for Sep 30, 2024, Spectral Medical Inc's Total Current Liabilities amounts to 33.9m CAD.

What is Spectral Medical Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
29%

Over the last year, the Total Current Liabilities growth was 964%. The average annual Total Current Liabilities growth rates for Spectral Medical Inc have been 150% over the past three years , 107% over the past five years , and 29% over the past ten years .

Back to Top